For patient_b with type 2 diabetes and a body mass index (BMI) of 28, it is recommended to consider the use of a glucagon-like peptide-1 receptor agonist (胰高糖素样肽-1受体激动剂) in addition to lifestyle interventions (生活方式干预) based on the SWRL rule. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.